ClinicalTrials.gg
RecruitingNCT04187443Updated Sep 29, 2025

MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema

A Phase 1 interventional study of MS-553 in Diabetic Macular Edema, Macular Edema and Type 2 Diabetes With Diabetic Macular Edema, sponsored by Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.. Recruiting at 3 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-29.

Sponsored by Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 72 studies in Macular Edema with a site in China — 18 open to participants now, 22 under way, 4 of them phase 3. Macular Edema · China.

Planned enrollment
53rd of 65
45 · median 140
Started
2020
with 4 others
Phase 1
9 of 72
4 open now
Primary completion
2026-10
later than 13 of 21 live
Registered
25th of 72
by date

Among the 72 studies in Macular Edema with a site in China, this one is the 53rd largest by planned enrollment of the 65 interventional ones that give a count, is one of 5 that started in 2020, is one of 9 in phase 1, reaches primary completion later than 13 of the 21 other live ones, and was the 25th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

18 of the 72 studies in Macular Edema with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Macular Edema with a site in China, or all of them as a file.
02

Study summary

This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema. Fifteen subjects with diabetic macular edema will be enrolled into each of three dose cohorts and will receive oral administration of MS-553 for 8 weeks.

03

Conditions studied

  • Diabetic Macular Edema
  • Macular Edema
  • Type 2 Diabetes With Diabetic Macular Edema
  • Type 1 Diabetes With Diabetic Macular Edema
  • Diabetic Retinopathy

Keywords

  • Diabetic Macular Edema
  • Macular Edema
  • Center-involved Diabetic Macular Edema
  • Center-involved DME
  • DME
  • Diabetic Retinopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of diabetes mellitus (type 1 or type 2) according to ADA or WHO diabetic diagnosis criteria
  • Subject has the ability to follow the study instructions and is likely to complete all required study procedures and visits;
  • All males and females must consent to pregnancy prevention during the study and qualified measures of . All females of must consent to a pregnancy test before entering the study.
  • Presence of central involved macular edema associated with diabetic retinopathy, i.e. diabetic macular edema (DME), as assessed by spectral domain optical coherence tomography (sd-OCT) of the central retina subfield thickness (CRT) at the Screening Visit (Centration must be confirmed by Investigators with signatures);
  • Best Corrected Visual Acuity (BCVA) score ≥ 34 letters (approximately 20/200 to 20/20 Snellen equivalent or better) using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity protocol, and assessed at the Screening Visit Visual acuity (VA);
  • Confirmation by the investigator that laser photocoagulation and anti-VEGF treatments are either declined by the patients or not needed and can be withheld for at least 3 months after the Screening Visit;
  • Ocular media and pupil dilation adequate to permit good quality retinal imaging as assessed at Screening Visit.

Exclusion criteria

Exclusion Criteria:

  • Subjects with unstable metabolic or blood pressure control
  • Subject with emaciation or obesity at Screening Visit: (BMI) \<18.5kg/m2 or >28kg/m2
  • Current use or likely need for medications know to be toxic to the lens, retina or optic nerve, including Deferoxamine, Chloroquine / hydroxychloroquine (Plaquenil), Tamoxifen, Phenothiazines and Ethambutol -
  • History of myocardial infarction or other cardiac event requiring hospitalization (unstable angina pectoris, etc.), cerebrovascular accident, , treatment for acute congestive heart failure or any arrhythmia within 4-months prior to Screening Visit;
  • Any situation that may in the opinion of the investigator preclude the safe administration of the study medication, adherence to the scheduled study visits, safe participation in the study or affect the results of the study as assessed at Screening Visit;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    MS-553 low dose

    low dose of MS-553 taken orally

    Drug: MS-553

  • Experimental
    MS-553 mid dose

    mid dose of MS-553 taken orally

    Drug: MS-553

  • Experimental
    MS-553 high dose

    high dose of MS-553 taken orally

    Drug: MS-553

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment-emergent adverse events

    Time frame: Baseline to Day 56

Secondary outcomes

  1. Mean change in the central retina subfield thickness (CRT)

    Time frame: Baseline to Day 56

  2. Mean change in the retinal volume

    Time frame: Baseline to Day 56

  3. Proportion of patients with >20% reduction in CRT

    Time frame: Baseline to Day 56

  4. Proportion of patients with resolution of central involved macular edema

    Time frame: Baseline to Day 56

  5. Average mean change in best corrected visual acuity

    Time frame: Baseline to Day 56

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Oct 2026, 76 months after the start.

Of 25 phase 1 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's planned 76 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2019
First posted
Dec 5, 2019
StartActual
Jun 2, 2020
Primary completionEst.
Oct 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Sep 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04187443
Lead sponsor
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Collaborators
Fountain Medical Development Co., Ltd.
Responsible party
Sponsor
First posted
Dec 5, 2019
Start date
Jun 2, 2020
Primary completion
Oct 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Sep 29, 2025

Study contacts

Ling Yang
Contact
yangling@relin.cn
+8613421382136
Kai Zhang, MD
study director · Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PKC-beta Inhibitor MS-553

Start the discussion